IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#259
Positioning
Market Dominance
Services
Business Services
$542M
Robert T. Dechant
IBEX Limited provides end-to-end technology-enabled customer lifecycle experience solutions. The company provides ibex Connect, a customer engagement solution that comprises customer service, technical support, revenue generation, and other value-added outsourced back-office services. As of October 1, 2021, the company operated 33 customer engagement and three customer acquisition delivery centers.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = IBEX ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$YALA Yalla Group Ltd | 75 | 89 | 99 | 80 | - | - | 21.3% | 18.6% | 64.5% | 35.7% | 39.5% | 6.5% | 0.0% | 0.0x | $644M | VS | |
$GRVY GRAVITY Co., Ltd. | 75 | 82 | 96 | 71 | - | - | 15.4% | 12.6% | 38.7% | 17.1% | 17.0% | -39.7% | 0.0% | 0.0x | $439M | VS | |
$ISSC INNOVATIVE SOLUTIONS & SUPPORT INC | 73 | 81 | 88 | 94 | 25.0x | 14.1x | 28.1% | 16.8% | 48.1% | 23.8% | 18.5% | 78.6% | 0.0% | 37.0x | $220M | VS | |
$AER AerCap Holdings N.V. | 72 | 60 | 87 | 84 | - | - | 12.4% | 2.9% | 100.0% | 28.2% | 26.2% | 5.5% | 0.8% | 264.0x | $19.4B | VS | |
$HCSG HEALTHCARE SERVICES GROUP INC | 72 | 74 | 88 | 88 | 7.1x | 6.1x | 28.9% | 20.8% | 20.8% | 9.9% | 9.3% | 8.5% | 0.0% | 1.0x | $1.2B | VS | |
$LQDT LIQUIDITY SERVICES INC | 72 | 90 | 88 | 68 | 24.9x | 14.3x | 14.6% | 7.8% | 43.8% | 7.4% | 5.9% | 31.2% | 0.0% | 0.0x | $857M | VS | |
$TRTNpA Triton International Ltd | 71 | 70 | 89 | 70 | - | 1.7x | 18.0% | 4.6% | 97.3% | 52.2% | 32.7% | -3.4% | 0.0% | 271.0x | $8.0B | VS | |
$EDU New Oriental Education & Technology Group Inc. | 71 | 83 | 52 | 77 | - | - | 9.4% | 4.9% | 55.5% | 8.7% | 7.7% | 13.6% | 1.3% | 7.0x | $78.0B | VS | |
$NTES NetEase, Inc. | 71 | 88 | 93 | 68 | - | - | 22.1% | 15.6% | 62.5% | 28.1% | 28.7% | -1.0% | 2.8% | 9.0x | $56.6B | VS | |
$UTI UNIVERSAL TECHNICAL INSTITUTE INC | 70 | 86 | 86 | 72 | 43.2x | 16.0x | 21.4% | 8.0% | 100.0% | 10.0% | 7.5% | 14.1% | 0.0% | 27.0x | $1.8B | VS | |
$IBEX IBEX Ltd | 66 | 81 | 74 | 74 | 9.4x | 7.7x | 27.4% | 14.3% | 100.0% | 8.7% | 7.2% | 29.5% | 0.0% | 91.0x | $542M | ||
| SECTOR BENCH | - | - | - | - | - | 23.7x | 11.7x | 5.3% | 1.9% | 59.6% | 3.5% | 2.3% | 7.8% | 0.0% | 0.3x | - | REF |
IBEX Ltd (IBEX) receives a "Buy" rating with a composite score of 65.7/100. It ranks #259 out of 7,333 stocks in our coverage universe and carries a 4-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Robert T. Dechant
Chief Executive Officer
Labor Force
30,000
81
34
68
Audit Verdict: Average governance indicators based on financial metrics.
No recent insider transactions available for IBEX
Headcount
30.0K
HQ Base
Pending Verification
Outperforming peers — winners tend to keep winning over 3-12 months
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Top-rated overall — multiple factors aligned for strong entry
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Services sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for IBEX.
View All RatingsMaterial decline in asset turnover efficiency detected
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 81 | 95 | -14DRAG |
| MOMENTUM | 74 | 83 | -9DRAG |
| VALUATION | 74 | 84 | -10DRAG |
| INVESTMENT | 34 | 48 | -14DRAG |
| STABILITY | 68 | 73 | -5NEUTRAL |
| SHORT INT | 71 | 86 | -15DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 27.4% (sector 5.3%)
GM 100% vs sector 60%, OM 9% vs sector 4%
Capital turnover N/A
Rev growth 30%, 7yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
IBEX Ltd receives a Buy rating with a composite score of 65.7/100 and 4 out of 5 stars, ranking #259 of 7,333 stocks in our universe. IBEX displays a favorable combination of factors that positions it above the majority of the market. While not without risk, the quantitative profile supports a constructive outlook.
IBEX earns a quality score of 81/100, indicating above-average business quality. The company reports a return on equity of 27.4% (sector avg: 5.3%), gross margins of 100.0% (sector avg: 59.6%), net margins of 7.2% (sector avg: 2.3%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
IBEX carries a solid value score of 74/100, pointing to an attractively priced stock relative to peers. Key valuation metrics include a P/E ratio of 9.37x, an EV/EBITDA of 7.71x, a P/B ratio of 2.56x. This score suggests reasonable compensation for the risks involved, with potential upside if the market recognizes the stock's underlying worth.
IBEX Ltd's investment score of 34/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 29.5% vs. a sector average of 7.8% and a return on assets of 14.3% (sector: 1.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
IBEX shows strong momentum characteristics with a score of 74/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth stands at 29.5% year-over-year, while a beta of 0.64 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
IBEX shows good financial stability with a score of 68/100. Key stability metrics include a beta of 0.64 and a debt-to-equity ratio of 91.00x (sector avg: 0.3x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
IBEX carries a short interest score of 71/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include elevated leverage (D/E: 91.00x), small-cap liquidity risk. At $542M market cap (small-cap), IBEX Ltd offers reasonable institutional liquidity.
IBEX Ltd is a small-cap company in the Services sector, ranked #27 of 50 in its sector (46th percentile) and #259 of 7,333 overall (96th percentile). Key comparisons include ROE of 27.4% exceeding the 5.3% sector median and operating margins of 8.7% above the 3.5% sector average. This below-median ranking suggests IBEX faces competitive challenges relative to stronger Services peers.
Quant Factor Profile
Key factor gap
Quality (81) vs Investment (34) — closing this gap could shift the rating.
RANK #27 OF 50 IN CONSUMER DISCRETIONARY
EV/EBITDA 34% BELOW SECTOR MEDIAN (FAVORABLE)
ROE 415% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 68% ABOVE SECTOR MEDIAN (FAVORABLE)
AUDIT DATA AS OF DEC 31, 2025 (Q3 FY2025)
We rate IBEX Ltd (IBEX) as a Buy with a composite score of 65.7/100 at a current price of $27.75. The stock scores above average across the majority of our six quantitative factors and ranks #259 out of 7,333 stocks in our universe, reflecting a favorable risk-reward profile.
The rating is primarily driven by strength in quality (81th percentile) and value (74th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (34th percentile) and stability (68th percentile) tempers our overall conviction. We assign a Narrow Moat rating (49/100), Low uncertainty, and Standard capital allocation.
Key items to watch: sustainability of the current growth rate. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
IBEX Ltd holds a mid-tier position (#27 of 50) within the Services sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 65.7/100 places it at rank #259 in our full 7,333-stock universe. At $542M in market capitalization, IBEX Ltd is a small-cap player in the Services space, which limits certain scale advantages but may allow for more agile strategic execution.
The near-term outlook is constructive, with revenue growing at 30% and momentum in the 74th percentile confirming positive market sentiment and institutional accumulation. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy. Investment factor at the 34th percentile indicates reinvestment patterns that investors should monitor for sustainability.
The margin cascade tells an important story: gross margins of 100% (+40.4pp vs sector) narrow to operating margins of 9% (+5.2pp vs sector) and net margins of 7.2%, yielding a gross-to-net conversion rate of 7%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $27.75, IBEX Ltd appears undervalued relative to its fundamentals. Our value factor score of 74/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The stock screens as attractively priced on a majority of these measures, suggesting the market may be underappreciating the underlying fundamentals.
The stock currently trades at a P/E of 9.4x (a 61% discount to the sector median of 23.7x), EV/EBITDA of 7.7x (discounted to peers), P/B of 2.6x, P/S of 0.7x. The below-sector P/E suggests possible undervaluation or the market pricing in near-term headwinds.
The stock's Buy rating (composite score 65.7/100) reflects broad-based quantitative strength, placing it in the top 20% of our 7,333-stock universe.
Gross margins of 100% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Returns on equity of 27.4% exceed the cost of equity for most companies, indicating genuine shareholder value creation and a reinvestment engine that compounds wealth over time.
Revenue growth of 30% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
A value factor score of 74/100 suggests the market is underpricing these fundamentals, creating a potential margin of safety for new investors.
We assign a Low uncertainty rating to IBEX Ltd. The company exhibits strong financial stability with a beta of 0.64, and a stability factor in the 68th percentile. The predictable nature of the business model and solid financial position reduce the range of potential outcomes, giving us confidence in our fair value estimate.
Specific risk factors that inform our assessment include: low beta of 0.64 — while defensive, this may indicate limited upside participation in bull markets. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 68th percentile and quality factor at the 81th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 100% provide a buffer against cost pressures; above-average stability (68th percentile) suggests predictable business dynamics. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate IBEX Ltd's capital allocation as Standard. Management has shown adequate — though not exceptional — stewardship of shareholder capital. Returns on equity stand at 27.4%, and the balance sheet is managed within acceptable parameters (D/E: 91%). Exemplary allocators typically sustain ROE above 20% and D/E below 50%; IBEX Ltd falls short on at least one dimension.
There is room for improvement in optimizing the capital structure or enhancing shareholder returns. Absent a dividend, the overall capital allocation framework would benefit from either higher reinvestment returns, improved balance sheet efficiency, or increased shareholder distributions. We will monitor for signs of strategic improvement that could warrant an upgrade.
In summary, IBEX Ltd receives a Buy rating with a composite score of 65.7/100 (rank #259 of 7,333). Our quantitative framework assigns a Narrow Moat (49/100, trend: stable), Low uncertainty, and Standard capital allocation. The average factor score across quality, value, momentum, stability, and investment is 66/100.
Our analysis supports a constructive view on IBEX Ltd. The combination of identifiable competitive advantages, low uncertainty, and standard capital allocation creates a risk-reward profile that favors accumulation at current levels. We recommend investors consider adding this name to portfolios aligned with the stock's risk profile.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign IBEX Ltd a Narrow Moat rating with a composite moat score of 49/100. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that IBEX Ltd can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being growth durability at 16.3/20.
The strongest moat sources are growth durability (16.3/20) and economic value creation (14.5/20). Rev growth 30%, 7yr history. ROE proxy 27.4% (sector 5.3%). These pillars form the core of IBEX Ltd's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and financial resilience (6.3/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect IBEX Ltd's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 100% providing a solid profitability foundation, robust top-line growth of 30% expanding the revenue base, returns on equity of 27.4% driving shareholder value creation. The margin cascade from 100% gross to 9% operating to 7.2% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that the profit engine is high-quality and likely sustainable, with the quality factor at the 81th percentile.
The margin profile shows gross margins of 100%, operating margins of 9%, net margins of 7.2%. Return metrics include ROE of 27.4% and ROA of 14.3%. Relative to the Services sector, gross margins are 40.4 percentage points above the sector median of 60%, and ROE of 27.4% compares to a sector median of 5.3%.
The balance sheet reflects above-average leverage with D/E of 91%, revenue growth of 30%. The sector median D/E is 0%, putting IBEX Ltd at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Elevated short interest (71th percentile) indicates that sophisticated market participants are betting against the stock.
It might be of some concern to shareholders to see the IBEX Limited ( NASDAQ:IBEX ) share price down 21% in the last...
IBEX (NasdaqGM:IBEX) has put up another solid quarter, with Q2 2026 revenue at US$164.2 million and basic EPS of US$0.91, backed by trailing 12 month EPS of US$3.31 on US$603.3 million of revenue. The company has seen quarterly revenue move from US$140.7 million in Q2 2025 to US$164.2 million in Q2 2026, while basic EPS stepped up from US$0.61 to US$0.91 over the same stretch. This sets the stage for investors to weigh steady top line progress against earnings that tie into a 7.3% net margin...
IBEX Ltd (IBEX) reports impressive revenue and EPS growth, driven by strategic client wins and AI advancements, despite challenges in telecommunications and expansion costs.
BOSTON & TEL AVIV, Israel, February 18, 2026--Ibex Medical Analytics (Ibex), the global leader in clinical-grade AI-powered pathology, today announced continued commercial momentum and expanding global adoption alongside a leadership transition designed to accelerate the company’s next phase of growth. Effective immediately, Yair Heller, formerly Chief Operating Officer, has been appointed Chief Executive Officer, and co-founder Joseph Mossel will lead Ibex’s rapidly expanding biopharma division
Operator: Welcome to the IBEX Second Quarter FY 2026 Earnings Conference Call. [Operator Instructions] Please be advised that today
Above 50MA
37.18%
Net New Highs
+51081